VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026

Valneva SE reported its share capital composition as of May 31, 2026, with 189.77 million ordinary shares and double voting rights on 1,859 shares. The company also announced Q1 2026 financial results showing product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from an April reserved offering.

06/03/2026, 12:00 PM • GlobeNewswire

VALNEVA : Déclaration d’actions et de droits de vote - Statut au 31 mai 2026

Valneva SE reported Q1 2026 financial results with total product sales of €30.5 million and a cash position of €105.3 million as of end March 2026, excluding proceeds from a successful reserved offering completed in April 2026. The company announced participation in U.S. and European investor conferences in June 2026.

06/03/2026, 12:00 PM • GlobeNewswire

Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2026

Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.

04/03/2026, 2:30 AM • GlobeNewswire

Declaration of shares and voting rights of Valneva SE – March 2026

Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in people aged five years and older during Phase 3 VALOR trial. The companies also announced Valneva's participation in the 26th World Vaccine Congress in Washington DC.

04/03/2026, 2:30 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN

Pomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.

03/24/2026, 5:49 PM • GlobeNewswire

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Valneva and Pfizer's Phase 3 VALOR trial for their Lyme disease vaccine failed to meet its primary endpoint due to fewer cases being accrued than expected. However, secondary analyses showed clinically meaningful efficacy of 73-75%, and Pfizer plans to proceed with regulatory submissions. Valneva shares fell 35.27% on the news, trading significantly below key moving averages.

03/23/2026, 10:35 AM • Benzinga

VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026

Valneva has voluntarily withdrawn its IXCHIQ chikungunya vaccine BLA (Biologics License Application) and IND (Investigational New Drug) in the United States. The company is continuing to review global product opportunities based on medical need and commercial attractiveness. This decision comes as Valneva and Instituto Butantan announced initiation of a pilot vaccination campaign in Brazil with the single-shot vaccine.

02/06/2026, 2:30 AM • GlobeNewswire

VALNEVA Declaration of shares and voting rights: January 31, 2026

Valneva has voluntarily withdrawn its Biologics License Application (BLA) and Investigational New Drug (IND) for IXCHIQ chikungunya vaccine in the United States. Simultaneously, the company is advancing a pilot vaccination campaign with Instituto Butantan in Brazil, continuing to evaluate the global product opportunity based on medical need and commercial attractiveness.

02/06/2026, 2:30 AM • GlobeNewswire

VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025

Valneva is consolidating its French operations at its Lyon site and finalizing R&D consolidation in Vienna. The company also reported positive Phase 2 results for its Lyme Disease vaccine candidate, showing sustained antibody levels and no safety concerns.

12/05/2025, 12:34 PM • GlobeNewswire

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva reported changes in its share capital and voting rights, including the issuance of new ordinary shares through stock option exercises and transfers of shares between November 6-28, 2025.

12/05/2025, 12:34 PM • GlobeNewswire

VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025

Valneva reported positive results from a Phase 1 trial of its second-generation Zika vaccine candidate, demonstrating an improved immune response compared to previous iterations.

11/05/2025, 12:00 PM • GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2025

Valneva reported changes in its share capital and voting rights, with a total of 171,958,275 ordinary shares and 187,722,356 net voting rights after transfers and free share attributions.

11/05/2025, 12:00 PM • GlobeNewswire

VALNEVA Declaration of shares and voting rights: September 30, 2025

Valneva reported a change in its share composition, with 171,854,856 ordinary shares and a transfer of 653 shares with double voting rights between September 1-18, 2025.

10/06/2025, 1:30 AM • GlobeNewswire

VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 2025

Valneva reported its shares and voting rights status as of September 30, 2025, with 171,854,856 ordinary actions and 187,978,646 total voting rights, noting minor changes in share ownership and voting rights.

10/06/2025, 1:30 AM • GlobeNewswire

Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight

DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.

10/01/2025, 1:00 PM • GlobeNewswire